Key Takeaways KMTS announced a collaboration with Biobeat, including an exclusive license and a $5M Series B investment.KMTS integrates FDA-cleared cuffless blood pressure monitoring into the ASSURE WCD for at-home recovery.Per Kestra, ACE-PAS data reflects 72% hypertensive patients, highlighting BP challenges post-cardiac events.Kestra Medical Technologies, Ltd.(KMTS) announced a collaboration with Biobeat Technologies, Ltd. to improve patient monitoring and diagnosis insights for people who rely on the AS ...

Company Overview - Kestra operates in a significantly underserved market with an urgent need for its clinical solutions [2] - The company has a differentiated and clinically proven product offering [3] - Kestra's total addressable market (TAM) is approximately $10 billion in the U.S., with a larger market size internationally [3] Market Opportunity - Current market penetration is estimated at $1 billion, representing a substantial opportunity for growth as a new entrant [3] - The market previously operated as a monopoly, indicating potential for disruption and scalability for Kestra's business model [4] Product Offering - The first product launched by Kestra is the cardiac recovery platform, which includes the ASSURE Wearable Cardioverter [5] - The company positions itself as a wearable medical device and digital healthcare provider [4] Leadership and Strategy - Kestra boasts a proven leadership team with prior experience in successfully navigating similar market landscapes [4] - The business model is characterized by attractive unit economics, enhancing its scalability potential [4]

Kestra Medical Technologies (NasdaqGS:KMTS) FY Conference January 13, 2026 05:15 PM ET Company ParticipantsBrian Webster - CEOConference Call ParticipantsRobbie Marcus - MedTech AnalystRobbie MarcusGood afternoon, everyone. I'm Robbie Marcus, the MedTech analyst at JPMorgan. Happy to bring up CEO of Kestra, Brian Webster. He's going to do a presentation, then we'll do some Q&A after.Brian WebsterSounds good. Thanks, Robbie. OK, thanks, Robbie. Hello, everyone. Good afternoon. You guys are coming up on midpo ...

KIRKLAND, Wash., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced a strategic collaboration with Biobeat Technologies, Ltd. to expand diagnostic insight for patients prescribed the ASSURE® Wearable Cardioverter Defibrillator (WCD). The agreement is anchored by an exclusive license and co-development arrangement and includes a $5 million equity investment in Biobeat’s recently announced Serie ...

KIRKLAND, Wash., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 at 2:15 p.m. Pacific Time. Interested parties may access the live webcast and replay of the presentation by visiting the Kestra Medical Technologies investor relations website. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable ...

Kestra Medical Technologies (NasdaqGS:KMTS) Q2 2026 Earnings Call December 11, 2025 04:30 PM ET Company ParticipantsStephanie Piazzola - VP of Equity Research Medical TechnologyVaseem Mahboob - CFOBrian Webster - President and CEODavid Roman - Managing DirectorNeil Bhalodkar - VP of Investor RelationsNone - Company RepresentativeConference Call ParticipantsLarry Biegelsen - Senior Medical Device Equity Research AnalystMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystMichae ...

Kestra Medical Technologies (NasdaqGS:KMTS) Q2 2026 Earnings Call December 11, 2025 04:30 PM ET Company ParticipantsStephanie Piazzola - VP of Equity Research Medical TechnologyVaseem Mahboob - CFOBrian Webster - President and CEODavid Roman - Managing DirectorNeil Bhalodkar - VP of Investor RelationsNone - Company RepresentativeConference Call ParticipantsLarry Biegelsen - Senior Medical Device Equity Research AnalystMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystMichae ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2026 was $22.6 million, representing a 53% increase compared to the prior year period [6][18] - Gross margin reached 50.6%, up 11 points year over year, marking the first time it surpassed 50% [7][19] - The company expects continued gross margin expansion, aiming for over 70% in the coming years [8][19] Business Line Data and Key Metrics Changes - Approximately 4,700 prescriptions were written for the Assure system in Q2 2026, contributing to revenue growth [6] - Revenue growth was driven by a 54% year-over-year increase in prescriptions, reflecting market share gains and activation of new accounts [18] Market Data and Key Metrics Changes - The wearable cardioverter defibrillator (WCD) market is underutilized, with only 14% of the eligible U.S. addressable market currently receiving therapy [9] - The WCD market growth has accelerated to low double digits, indicating a multi-billion-dollar market potential in the coming years [13] Company Strategy and Development Direction - The company is focused on expanding its sales organization to penetrate existing accounts and attract new prescribers [13][14] - The strategy includes enhancing revenue cycle management capabilities and increasing the in-network patient mix, which has improved from approximately 70% to the low 80s [15][19] - The company is investing in clinical evidence generation to influence clinical practice and guidelines [12][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong growth, supported by a robust clinical evidence base and an expanding market [17][21] - The company is increasing its fiscal year 2026 revenue guidance to $91 million, reflecting a growth of 52% compared to fiscal year 2025 [21][22] Other Important Information - GAAP operating expenses were $43.2 million in Q2, including non-recurring costs related to professional fees and the recent equity offering [20] - The company reported a GAAP net loss of $32.8 million for the quarter, compared to a loss of $20.6 million in the prior year [21] Q&A Session Summary Question: Guidance for the year and Q3 seasonality - Management discussed the importance of tracking performance on a daily, weekly, and monthly basis, emphasizing a focus on prescription volume growth and in-network mix [25] Question: Use of proceeds from the recent equity offering - The company plans to use the additional capital to strengthen its balance sheet and support key growth drivers [27] Question: Impact of AHA data on market growth - Management noted that the WCD market growth is low double digits, with anecdotal evidence suggesting an increase in clinician awareness and interest following the presentation of clinical data [29] Question: Path for guideline updates - Management clarified that while growth does not rely on guideline changes, they believe the clinical evidence warrants a review [33] Question: Prescription volume sustainability - Management expressed confidence in sustaining prescription growth above 50%, driven by ongoing penetration of existing accounts and the addition of new hospitals [41]

Financial Performance - Revenue for the three months ended October 31, 2025, was $22,565,000, representing a 53.5% increase from $14,710,000 in the same period of 2024[14] - Gross profit for the six months ended October 31, 2025, was $20,276,000, up from $10,030,000 in the prior year, indicating a 102.5% increase[14] - Total operating expenses for the three months ended October 31, 2025, were $43,179,000, compared to $24,964,000 in the same period of 2024, reflecting a 73.0% increase[14] - The net loss for the three months ended October 31, 2025, was $32,785,000, compared to a net loss of $20,621,000 for the same period in 2024, representing a 58.7% increase in losses[14] - For the six months ended October 31, 2025, the company incurred a net loss of $58,611 thousand, compared to a net loss of $40,944 thousand for the same period in 2024, representing an increase of 43% in losses year-over-year[31] - The net loss attributable to common shareholders for the six months ended October 31, 2025, was $58,611,000, compared to $45,958,000 for the same period in 2024[102] - Basic net loss per share attributable to common shareholders for the three months ended October 31, 2025, was $(0.64), compared to $(1.19) for the same period in 2024[102] Cash and Assets - Cash and cash equivalents decreased to $175,424,000 as of October 31, 2025, down from $237,595,000 as of April 30, 2025[12] - Total assets decreased to $246,701,000 as of October 31, 2025, from $295,744,000 as of April 30, 2025[12] - The company reported a total shareholders' equity of $164,081,000 as of October 31, 2025, down from $205,406,000 as of April 30, 2025[12] - As of October 31, 2025, the company had an accumulated deficit of $578,860 thousand[31] - The company had cash and cash equivalents of $175,424,000 as of October 31, 2025, down from $237,595,000 as of April 30, 2025[69] Operating Activities - Cash used in operating activities for the six months ended October 31, 2025, was $44,617 thousand, up from $35,555 thousand in 2024, indicating a 25.8% increase in cash outflow[31] - The company has experienced negative operating cash flows since inception, with net cash used in operating activities totaling $44,617 thousand for the six months ended October 31, 2025[31] Shareholder Equity and Stock Compensation - The company incurred share-based compensation expenses of $13,232 thousand for the six months ended October 31, 2025, compared to $1,499 thousand for the same period in 2024, reflecting a significant increase[21] - Total share-based compensation expense for the three months ended October 31, 2025, was $8,653,000, compared to $1,122,000 for the same period in 2024[93] - The company granted 2,251,618 restricted stock units during the six months ended October 31, 2025, with a weighted average grant date fair value of $16.26[87] - The total unrecognized compensation cost related to unvested market-based restricted stock units was $3,180,000, expected to be recognized over approximately 1.71 years[92] - As of October 31, 2025, there was $32,843,000 of total unrecognized compensation cost related to unvested restricted units expected to be recognized over approximately 2.68 years[89] Debt and Financing - The Company entered into a Credit Agreement on September 29, 2023, providing a Senior Secured Delayed Draw Term Loan Facility of up to $60 million, maturing on September 29, 2028[62] - The Company drew an initial $45 million from the Term Loan 2024 and incurred a facility fee of $600,000 upon the first draw[63] - As of October 31, 2025, the total long-term debt was $41,873,000, an increase from $41,098,000 as of April 30, 2025[68] - The Company recognized total expenses related to the Term Loan 2024 of $3,783,000 for the six months ended October 31, 2025, compared to $3,779,000 for the same period in 2024[68] - The fair value of long-term debt, net of discounts, was approximately $48,330,000 as of October 31, 2025, compared to $47,330,000 as of April 30, 2025[70] Market and Product Strategy - The company plans to continue expanding the commercialization of its ASSURE WCD and associated products as part of its Cardiac Recovery System platform[8] - The company is focused on maintaining regulatory approvals for its products and plans to enter new markets[8] - The company faces risks related to market acceptance, manufacturing scalability, and competition that could impact future performance[8] Other Financial Information - The Company recorded a provision for income taxes of $67,000 for the six months ended October 31, 2025, with an effective tax rate of 0.11%[94] - The Company completed a public offering on December 4, 2025, issuing 6,900,000 common shares at $23.00 per share, resulting in net proceeds of $149.2 million[103] - As of October 31, 2025, there were 7,701,304 potentially dilutive securities outstanding, which were excluded from the computation of weighted-average shares due to their antidilutive impact[102] - The Company’s matching and discretionary contributions to the 401(k) Plan totaled $1,025,000 for the six months ended October 31, 2025[99] - The Company has provided a full valuation allowance against its net deferred tax assets as of October 31, 2025, indicating that realization is not more likely than not[95]

Financial Performance - Kestra Medical Technologies, Ltd. announced preliminary estimated financial results for the fiscal quarter ended October 31, 2025[6]. - The report includes forward-looking statements regarding the company's financial performance and market adoption of its products[8]. - The company has not provided specific numerical guidance or performance metrics in this report[8]. Company Classification and Risks - The company is classified as an emerging growth company under the Securities Act of 1933[5]. - The company faces risks related to its limited operating history and history of net losses[8]. - There are uncertainties regarding the company's ability to achieve substantial market adoption of its products[8]. - The company is dependent on a limited number of suppliers, which poses additional risks[8]. Manufacturing and Production - The company must adapt its manufacturing and production capacities to evolving demand patterns[8]. Forward-Looking Statements - The company has no obligation to publicly update any forward-looking statements unless required by law[8]. - The press release dated December 1, 2025, is incorporated by reference[6].